Onboarding a virtual EA for your pharmaceutical and biotech business is the highest-leverage action you take in the entire EA relationship. A well-structured onboarding compresses months of ramp-up time into weeks. A poorly structured onboarding produces months of frustration while your EA guesses at context you never provided.
Pharmaceutical CEO operations are complex enough that an EA without adequate context cannot perform at their potential, regardless of their capability. This guide gives you the specific onboarding steps and content that produce fast, effective EA ramp-up in a pharmaceutical environment.
The Onboarding Investment: How Much Time Is Right
For a pharmaceutical and biotech CEO, the right onboarding investment is 5 to 12 hours spread across the first two weeks. That is:
- One 90-minute structured briefing session in the first one to two days
- Three to four shorter (30 to 45 minute) follow-up context sessions during week two
- Written documentation that your EA can reference independently as they work
This investment is front-loaded, concentrated in the first two weeks, and then transitions to shorter ongoing feedback sessions as the relationship matures. The total time investment is recovered within the first month as your EA reaches operational effectiveness faster than an under-onboarded EA would.
The Onboarding Briefing: What to Cover
Company Context and Pharmaceutical Stage
Your EA needs to understand what your company does, where you are in the development cycle, and what your most important near-term milestones are. This does not require a scientific deep-dive. It requires enough context to understand why your schedule looks the way it does and what the significant events in the next 12 months are.
Prepare a one-page company overview covering: therapeutic area, development stage, pipeline overview, key upcoming milestones (regulatory submissions, data readouts, investor events), and the commercial or financial situation that shapes your current priorities.
The Regulatory Calendar
This is the most pharmaceutical-specific element of your EA’s context and the one that most strongly affects their scheduling effectiveness. Walk your EA through your regulatory calendar for the next 12 months:
- Upcoming FDA meeting requests and their expected response timelines
- PDUFA dates and what preparation they require from the CEO’s calendar perspective
- IND annual report deadlines
- Advisory committee appearances and preparation requirements
- Any EMA or other international regulatory interactions that affect your schedule
For each major regulatory event, describe how much preparation time in your calendar it requires. An FDA Type B meeting typically needs two to four weeks of preparation. An advisory committee appearance may need six to eight weeks. Your EA needs to understand these requirements to protect your schedule correctly.
Key Stakeholders
Create a stakeholder brief covering your 10 to 20 most important external relationships: institutional investors, board members, key scientific advisors, CRO partners, FDA contacts (where appropriate), and key opinion leaders.
For each stakeholder, provide: their name and organization, their relationship to you and the company, their communication preferences if relevant, and any sensitivities your EA should know about.
Your EA will interact with these individuals on your behalf, managing scheduling and logistics. The briefing ensures those interactions are handled with appropriate context.
Communication Standards
Your communication standards are the benchmark against which your EA’s drafting work will be evaluated. The most efficient way to communicate these standards is through examples.
Provide your EA with five to ten examples of excellent communications from your files: investor update emails, FDA scheduling requests, board correspondence, and partner communications. Mark up two or three of them with notes explaining why they are effective. This gives your EA a concrete standard to match rather than an abstract description to interpret.
Scheduling Preferences
Document your scheduling preferences with specificity:
- Which days should remain protected for focused work?
- What types of meetings can be scheduled at any time vs. specific windows?
- What buffer time do you require before and after specific meeting types?
- How far in advance should travel be booked?
- What is the procedure when two high-priority requests conflict?
An EA who knows your scheduling preferences manages your calendar with intelligence rather than just filling slots. This specificity pays dividends across thousands of scheduling decisions over the course of the relationship.
For a comprehensive overview of the benefits that strong EA onboarding produces for pharmaceutical executives, see benefits of EA for pharma. For guidance on selecting the right service model to support the kind of EA relationship this onboarding investment is designed to build, dedicated EA for pharma covers the dedicated model in detail.
Information Handling Protocols
Define explicitly what information your EA will encounter and how they should handle each category:
Investor communications: Who can receive them, what requires your review before sending, and what constitutes material information requiring special handling.
Regulatory materials: What pre-filing regulatory information exists in your document management system, who can access it, and what your EA should do if they are asked to share regulatory materials externally.
Clinical data: How your EA should handle documents or communications that contain clinical trial data, particularly pre-publication data.
Board materials: Access levels for board documents, confidentiality requirements, and distribution protocols.
This protocol is not just a legal protection. It is a practical guide that prevents your EA from making information-handling errors through uncertainty rather than through negligence.
The First Week: Calibration Tasks
After the initial briefing, assign your EA a set of calibration tasks in the first week that spans the range of work they will be doing regularly:
- Manage the scheduling of one complex multi-party meeting
- Draft a response to a routine investor scheduling inquiry
- Book travel for an upcoming pharmaceutical conference
- Prepare a weekly calendar summary for the following week
Evaluate each output specifically and provide immediate, precise feedback. This calibration week sets the norms for the relationship and tells your EA exactly what your standards are.
Research from McKinsey identifies onboarding quality as the primary predictor of early EA relationship effectiveness, and early effectiveness as a strong predictor of long-term relationship quality. The investment is not optional; it is foundational.
Ongoing Onboarding: The First 90 Days
The initial briefing gets your EA started. The first 90 days of regular feedback continues the onboarding process as they encounter new situations and build deeper context.
Maintain a weekly 15-minute check-in during the first 90 days. Use these sessions to provide feedback on the past week, preview the upcoming week, and surface any context gaps that have emerged. By day 90, these sessions should be shortening and transitioning to bi-weekly as the relationship reaches operational maturity.
Conclusion
Onboarding a virtual EA for your pharmaceutical and biotech business is a disciplined, high-return investment that determines the quality of the entire subsequent relationship. Cover the regulatory calendar, key stakeholders, communication standards, scheduling preferences, and information handling protocols in your initial briefing. Follow with calibration tasks and specific feedback in week one. Maintain regular check-ins through the first 90 days. Pharmaceutical CEOs who onboard deliberately achieve full EA effectiveness within 60 days; those who skip the investment spend six months wondering why their EA is not performing. Invest the 5 to 12 hours. It pays back many times over.
Related Reading
For further context, explore Onboard a Virtual EA for Your Automotive Business Today and Onboard a Virtual EA for Your Construction & Architecture Business Today.